Merck plans early generic licensing to speed access to once-monthly HIV PrEP pill in 129 LMICs - MRK News | RalliesMerck plans early generic licensing to speed access to once-monthly HIV PrEP pill in 129 LMICs
M
MRK• Merck outlines early access plans for investigational HIV PrEP pill
- Merck set early access plans for investigational once-monthly oral HIV PrEP alimatravir (MK-8527) ahead of Phase 3 completion.
- Strategy targets rapid, broad LMIC rollout post-clearance via royalty-free, non-exclusive generic licensing covering 129 countries.
- Plans call for regional manufacturing capacity in Africa and Latin America to strengthen supply resilience and support scale-up.
- Merck will invest early in its own manufacturing to shorten the gap between potential U.S. clearance and LMIC availability.
- Initial Merck supply is expected to bridge demand until licensed generics secure regulatory clearances and bring production online.
•
